Skye Bioscience, Inc. (SKYE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Skye Bioscience, Inc. (SKYE) Healthcare & Pipeline Overview

Skye Bioscience, Inc. is a biopharmaceutical company specializing in cannabinoid-based therapeutics, with a focus on ophthalmology. Their lead candidate, SBI-100, targets glaucoma and ocular hypertension and is currently in Phase I trials, positioning them in the competitive biotechnology sector with a novel approach to eye disease treatment.

What Is the Investment Thesis for SKYE?

Skye Bioscience presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead product candidate, SBI-100, targeting glaucoma and ocular hypertension, is currently in Phase I trials. Successful completion of these trials and subsequent phases could lead to significant market value appreciation. The development of SBI-200, a preclinical asset aimed at treating various eye diseases, offers further potential upside. However, the company's small market capitalization of $9.85M and the inherent risks associated with drug development, including clinical trial failures and regulatory hurdles, must be considered. The company's success hinges on the successful clinical development and commercialization of its cannabinoid-based therapeutics. Investors should closely monitor the progress of SBI-100's clinical trials and the development of SBI-200.

Based on FMP financials and quantitative analysis

SKYE Key Highlights

SBI-100 is in Phase I clinical trials for the treatment of glaucoma and ocular hypertension, representing a key milestone in the company's development.

• SBI-200 is in preclinical development for various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy, expanding the company's potential market reach.
• The company rebranded from Emerald Bioscience, Inc. to Skye Bioscience, Inc. in January 2021, signaling a renewed focus on cannabinoid-based therapeutics.
• Skye Bioscience operates with a lean structure of 16 employees, allowing for focused and efficient execution of its research and development programs.
• The company's market capitalization is $0.03 billion, reflecting its early-stage development and associated risks.

Who Are SKYE's Competitors?

SKYE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SKYE's Key Strengths?

Novel cannabinoid-based therapeutic approach.

• Focus on unmet needs in ophthalmology.
• Lead product candidate in Phase I clinical trials.
• Experienced management team.

What Are SKYE's Weaknesses?

Limited financial resources.

• Early-stage development with high risk of failure.
• Small market capitalization.
• Reliance on a limited number of product candidates.

What Could Drive SKYE Stock Higher?

Completion of Phase I clinical trials for SBI-100 in glaucoma and ocular hypertension.

• Initiation of Phase II clinical trials for SBI-100.
• Preclinical development of SBI-200 for various eye diseases.
• Potential strategic partnerships with larger pharmaceutical companies.
• Regulatory approvals for SBI-100 in key markets.

What Are the Key Risks for SKYE?

Financial-distress signal — its Altman Z-Score of -41.17 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for SBI-100 or SBI-200.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from established pharmaceutical companies.
• Limited financial resources.
• Changes in the regulatory landscape for cannabinoid-based therapeutics.

What Are the Growth Opportunities for SKYE?

• Expansion of SBI-100 into additional indications: Beyond glaucoma and ocular hypertension, SBI-100 may have potential applications in other ophthalmic conditions. Exploring these additional indications could significantly expand the market opportunity for SBI-100. The timeline for this expansion would depend on the results of ongoing and planned clinical trials, with potential new indications being explored within the next 3-5 years. The market size for additional ophthalmic indications could potentially double the existing market for glaucoma and ocular hypertension.
• Advancement of SBI-200 through preclinical and clinical development: SBI-200, currently in preclinical development, targets a range of eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Successful advancement of SBI-200 through preclinical and clinical trials could result in a valuable asset and expand the company's product pipeline. Preclinical studies are expected to continue over the next 1-2 years, with potential Phase I trials commencing within 2-3 years. The market size for these indications is substantial, with dry eye syndrome alone representing a multi-billion dollar market.
• Strategic partnerships and collaborations: Skye Bioscience could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources. Potential partnerships could be formed within the next 1-2 years, depending on the progress of clinical trials and the attractiveness of the company's assets. The financial impact of these partnerships could be significant, potentially providing hundreds of millions of dollars in funding.
• Geographic expansion: Initially focused on the US market, Skye Bioscience could expand its operations to other geographic regions, such as Europe and Asia, to increase its market reach. This expansion could occur following regulatory approvals in these regions, potentially within 3-5 years. The market size in these regions is substantial, representing a significant growth opportunity. The company would need to establish a presence in these regions through partnerships or direct investment.
• Development of novel cannabinoid-based molecules: Skye Bioscience could leverage its expertise in cannabinoid-based therapeutics to develop novel molecules targeting other diseases beyond ophthalmology. This could diversify the company's product pipeline and reduce its reliance on its existing assets. The timeline for developing new molecules would depend on research and development efforts, with potential new candidates being identified within the next 2-3 years. The market size for new therapeutic areas could be substantial, depending on the specific diseases targeted.

What Are SKYE's Competitive Advantages?

• Proprietary cannabinoid-based molecule platform.
• Patent protection for its drug candidates.
• First-mover advantage in the cannabinoid-based ophthalmology space.

What Does SKYE Do?

Skye Bioscience, Inc., founded in 2012 and headquartered in San Diego, California, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cannabinoid-based molecules. Originally named Emerald Bioscience, Inc., the company rebranded to Skye Bioscience in January 2021, signaling a renewed focus on its core mission. The company's primary focus is on addressing unmet needs in the treatment of infectious diseases, particularly those affecting the eye. Their lead product candidate, SBI-100, is currently undergoing Phase I clinical trials as a potential treatment for glaucoma and ocular hypertension, two prevalent conditions that can lead to irreversible vision loss. In addition to SBI-100, Skye Bioscience is also developing SBI-200, a preclinical asset aimed at treating and managing various other eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. These conditions represent significant market opportunities within the ophthalmology space. Skye Bioscience's strategy involves leveraging the therapeutic potential of cannabinoids to develop novel treatments that offer improved efficacy and safety profiles compared to existing therapies. The company operates with a lean structure, currently employing 16 individuals, allowing for focused and efficient execution of its research and development programs.

What Products and Services Does SKYE Offer?

• Discovers cannabinoid-based molecules for therapeutic use.
• Develops cannabinoid-based drugs targeting infectious diseases.
• Focuses on treatments for eye diseases like glaucoma and ocular hypertension.
• Conducts preclinical and clinical trials to evaluate drug safety and efficacy.
• Seeks regulatory approvals for its drug candidates.
• Commercializes approved drugs through partnerships or direct sales.

How Does SKYE Make Money?

• Develops and patents novel cannabinoid-based molecules.
• Outlicenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties on partnered products.

What Industry Does SKYE Operate In?

Skye Bioscience operates within the competitive biotechnology industry, specifically targeting the ophthalmology market. Similarly, the market for dry eye syndrome and other eye diseases represents a significant opportunity. Skye Bioscience's cannabinoid-based approach differentiates it from traditional pharmaceutical companies in the space. The company faces competition from established players with existing treatments, as well as other biotechnology companies developing novel therapies. Success in this market requires strong clinical data, regulatory approvals, and effective commercialization strategies.

Who Are SKYE's Key Customers?

• Patients suffering from glaucoma and ocular hypertension.
• Patients with uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy.
• Pharmaceutical companies seeking to expand their product portfolios.

Company Profile

Skye Bioscience, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Punit Dhillon. SKYE has traded publicly since 2015.

Skye Bioscience, Inc. (SKYE) Valuation Context

Valued at $9.85M, SKYE is classified as a micro-cap stock. Relative to its peer group, SKYE's quantitative score of 24/100 is below the peer average of 77/100.

Skye Bioscience, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.17 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Skye Bioscience, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.00.

SKYE Financials

SKYE Latest News

SKYE Analyst Consensus

SKYE MoonshotScore

Common Questions About SKYE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources